Therapeutic potential of targeting LAG-3 in cancer [PDF]
Journal for ImmunoTherapy of CancerImmune checkpoint inhibitors targeting negative regulatory checkpoints including programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 have produced significant improvements in progression-free survival (PFS) and overall survival in ...
Diwakar Davar +2 more
doaj +4 more sources
Frequencies of PD-1 and LAG-3 positive T cells in asthmatic children and their relationship with inflammatory cytokines [PDF]
Open MedicineThis study aimed to investigate the expression of programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) on CD4+ and CD8+ T cells in children with asthma and their relationship with Th2-associated inflammatory cytokines (IL-4, IL-
Huang Jie +4 more
doaj +2 more sources
Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging [PDF]
Biomarker ResearchBackground The low response rate of anti-PD-1 monoclonal antibodies (mAbs) in hepatocellular carcinoma (HCC) requires the development of combination immunotherapy strategies to improve their efficacy. This study aimed to use LAG-3-targeted PET imaging to
Zhen Quan +9 more
doaj +2 more sources
Frontiers in Immunology, 2022 LAG-3, a type of immune checkpoint receptor protein belonging to the immunoglobulin superfamily, is confirmed to be expressed on activated immune cells, mainly including activated T cells.
Jin-Ling Huo +4 more
exaly +3 more sources
LAG-3 palmitoylation-inducing dysfunction of decidual CD4+T cells is associated with recurrent pregnancy loss [PDF]
Molecular MedicineRecurrent pregnancy loss (RPL) profoundly impacts not only the physical health but also the psychological well-being of women. Despite its profound effects, the underlying pathophysiological mechanisms of RPL remain largely elusive, with few discernible ...
Liyuan Cui +5 more
doaj +2 more sources
Frequency of CD39+, LAG3+, and CTLA4+ Regulatory T Cells in Two Different Immunosuppressive Protocols in Renal Allograft Recipients (Sirolimus vs Mycophenolate mofetil): A Cohort Report [PDF]
Iranian Journal of Immunology, 2022 Background: Impaired renal function is considered as a significant risk factor for cardiovascular events in chronic kidney disease patients. Several immunosuppressive drugs are used in these patients, which necessitates to minimize the drug-related side ...
Yaghoub Mollaei-Kandelous +7 more
doaj +1 more source
Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements [PDF]
Biomarker ResearchTreatment based on immune checkpoint blockade has revolutionized cancer therapy. Despite the remarkable success achieved and the preclinical development of multiple checkpoint inhibitors targeting other checkpoints, only antibodies targeting the PD-1/PD ...
Alejandra Martínez-Pérez +4 more
doaj +2 more sources
OncoImmunology, 2021 Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8+ cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML).
Jana Rakova +14 more
doaj +1 more source
Сибирский онкологический журнал, 2023 Purpose: to study the level of LAG-3 expression on B-lymphocytes and the feasibility of using it as a marker for predicting response to therapy in patients with chronic lymphocytic leukemia (CLL).Material and Methods.
O. N. Selyutina +9 more
doaj +1 more source
PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
OncoImmunology, 2021 Concurrent blockade of different checkpoint receptors, notably PD-1 and CTLA-4, elicits greater anti-tumor activity for some tumor types, and the combination of different checkpoint receptor inhibitors is an active area of clinical research.
Christopher D. Zahm +3 more
doaj +1 more source